



**PB 93 of 2021**

## **National Health (Listed Drugs on F1 or F2) Amendment Determination 2021 (No. 6)**

---

I, Nikolai Tsyganov, Acting Assistant Secretary, Pricing and PBS Policy Branch, Technology Assessment and Access Division, Department of Health, delegate of the Minister for Health and Aged Care, make the following determination.

Dated                    27 August 2021

**NIKOLAI TSYGANOV**  
Acting Assistant Secretary  
Pricing and PBS Policy Branch  
Technology Assessment and Access Division  
Department of Health

---



---

# Contents

1 Name.....	1
2 Commencement .....	1
3 Authority.....	1
4 Schedules .....	1
<b>Schedule 1—Amendments</b>	<b>2</b>
<i>National Health (Listed Drugs on F1 or F2) Determination 2021 (PB 33 of 2021)</i>	2



---

## 1 Name

This instrument is the *National Health (Listed Drugs on F1 or F2) Amendment Determination 2021 (No. 6)*.

This instrument may also be cited as PB 93 of 2021.

## 2 Commencement

- (1) Each provision of this instrument specified in column 1 of the table commences, or is taken to have commenced, in accordance with column 2 of the table. Any other statement in column 2 has effect according to its terms.

Commencement information		
Column 1	Column 2	Column 3
Provisions	Commencement	Date/Details
1. The whole of this instrument	1 September 2021.	

Note: This table relates only to the provisions of this instrument as originally made. It will not be amended to deal with any later amendments of this instrument.

- (2) Any information in column 3 of the table is not part of this instrument. Information may be inserted in this column, or information in it may be edited, in any published version of this instrument.

## 3 Authority

This instrument is made under subsection 85AB(1) of the *National Health Act 1953*.

## 4 Schedules

Each instrument that is specified in a Schedule to this instrument is amended or repealed as set out in the applicable items in the Schedule concerned, and any other item in a Schedule to this instrument has effect according to its terms.

---

## **Schedule 1—Amendments**

### ***National Health (Listed Drugs on F1 or F2) Determination 2021 (PB 33 of 2021)***

#### **1 Schedule 1, after item dealing with Apraclonidine**

insert:

Apremilast

#### **2 Schedule 1, after item dealing with Carfilzomib**

insert:

Cariprazine

#### **3 Schedule 1, after item dealing with Dimethyl fumarate**

omit:

Diphtheria and tetanus vaccine, adsorbed, diluted for adult use

insert:

Diphtheria and tetanus vaccine, adsorbed, diluted for adult use

#### **4 Schedule 1, after item dealing with Insulin neutral**

omit:

Interferon alfa-2a

#### **5 Schedule 1, after item dealing with Lapatinib**

insert:

Ledipasvir with sofosbuvir

#### **6 Schedule 1, after item dealing with Mepolizumab**

omit:

Mercaptopurine

#### **7 Schedule 1, after item dealing with Mesna**

omit:

Methenamine

#### **8 Schedule 1, after item dealing with Nystatin**

insert:

Obeticholic acid

#### **9 Schedule 1, after item dealing with Ponatinib**

omit:

Posaconazole

---

**10 Schedule 1, after item dealing with Praziquantel**

insert:

Prednisolone acetate

**11 Schedule 1, after item dealing with Protein formula with carbohydrate, fat, vitamins and minerals**

insert:

Protein formula with vitamins and minerals, and low in potassium, phosphorus, calcium, chloride and vitamin A

**12 Schedule 1, after item dealing with Secukinumab**

insert:

Selexipag

**13 Schedule 1, after item dealing with Sodium phenylbutyrate**

omit:

Sofosbuvir

insert:

Sofosbuvir with velpatasvir

**14 Schedule 2, after item dealing with Memantine**

insert:

Mercaptopurine

**15 Schedule 2, after item dealing with Methadone**

insert:

Methenamine

**16 Schedule 2, after item dealing with Polyvinyl alcohol**

insert:

Posaconazole